Effect of atorvastatin on endothelium-dependent vasodilation in patients with coronary artery disease.
Vita
Joseph A
JA
Evans Department of Medicine, Whitaker Cardiovascular Institute, Boston University School of Medicine, Massachusetts, USA. jvita@bu.edu
Gokce
Noyan
N
Duffy
Stephen J
SJ
Kahn
David
D
Tomasian
Douglas
D
Palmisano
Joseph
J
Thomas
Shane
S
Holbrook
Monika
M
Keaney
John F
JF
D000368:Aged; D000069059:Atorvastatin; D001783:Blood Flow Velocity / Q000187:drug effects / Q000502:physiology; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology*; D004311:Double-Blind Method; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D005260:Female; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009131:Muscle, Smooth, Vascular / Q000098:blood supply* / Q000378:metabolism / Q000503:physiopathology; D005996:Nitroglycerin / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use*; D013577:Syndrome; D013997:Time Factors; D016896:Treatment Outcome; D014664:Vasodilation / Q000187:drug effects*; D014665:Vasodilator Agents / Q000627:therapeutic use
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D011758:Pyrroles; D014665:Vasodilator Agents; D000069059:Atorvastatin; D005996:Nitroglycerin